EdgarLookup

MASIMO CORP — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that MASIMO CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
-46.2%
Profit Margin
Net income ÷ revenue
-8.9%
Return on Assets
Net income ÷ assets
1.36x
Debt-to-Equity
Total liabilities ÷ equity
+6.6%
Revenue Growth
Year over year

Revenue

Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.

Fiscal Year Period End Value Filed
FY2021 Jan 1, 2022 $327.58M Feb 16, 2022
FY2021 Oct 2, 2021 $307.41M Feb 16, 2022
FY2021 Jul 3, 2021 $305.12M Feb 16, 2022
FY2021 Apr 3, 2021 $299.04M Feb 16, 2022
FY2020 Jan 2, 2021 $295.05M Feb 23, 2021
FY2021 Sep 26, 2020 $278.11M Feb 16, 2022
FY2021 Jun 27, 2020 $300.95M Feb 16, 2022
FY2021 Mar 28, 2020 $269.63M Feb 16, 2022
FY2020 Dec 28, 2019 $247.51M Feb 23, 2021
FY2020 Sep 28, 2019 $229.01M Feb 23, 2021

Revenue

Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.

Fiscal Year Period End Value Filed
FY2025 Jan 3, 2026 $1.53B Feb 27, 2026
FY2025 Dec 28, 2024 $1.40B Feb 27, 2026
FY2025 Dec 30, 2023 $1.28B Feb 27, 2026
FY2024 Dec 31, 2022 $2.04B Feb 25, 2025
FY2023 Jan 1, 2022 $1.24B Feb 28, 2024
FY2022 Jan 2, 2021 $1.14B Mar 1, 2023

Gross Profit

Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.

Fiscal Year Period End Value Filed
FY2025 Jan 3, 2026 $945.20M Feb 27, 2026
FY2025 Dec 28, 2024 $794.30M Feb 27, 2026
FY2025 Dec 30, 2023 $765.60M Feb 27, 2026
FY2024 Dec 31, 2022 $1.06B Feb 25, 2025
FY2021 Jan 1, 2022 $214.90M Feb 16, 2022
FY2021 Oct 2, 2021 $203.66M Feb 16, 2022
FY2021 Jul 3, 2021 $192.91M Feb 16, 2022
FY2021 Apr 3, 2021 $196.88M Feb 16, 2022
FY2020 Jan 2, 2021 $186.93M Feb 23, 2021
FY2021 Sep 26, 2020 $178.93M Feb 16, 2022

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 Jan 3, 2026 ($151.50M) Feb 27, 2026
FY2025 Dec 28, 2024 ($304.90M) Feb 27, 2026
FY2025 Dec 30, 2023 $81.50M Feb 27, 2026
FY2024 Dec 31, 2022 $143.50M Feb 25, 2025
FY2021 Jan 1, 2022 $68.26M Feb 16, 2022
FY2021 Oct 2, 2021 $57.77M Feb 16, 2022
FY2021 Jul 3, 2021 $50.24M Feb 16, 2022
FY2021 Apr 3, 2021 $53.38M Feb 16, 2022
FY2020 Jan 2, 2021 $70.67M Feb 23, 2021
FY2021 Sep 26, 2020 $49.41M Feb 16, 2022

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2025 Jan 3, 2026 $310.00M Feb 27, 2026
FY2025 Dec 28, 2024 $63.00M Feb 27, 2026
FY2025 Dec 30, 2023 $166.00M Feb 27, 2026
FY2024 Dec 31, 2022 $210.00M Feb 25, 2025
FY2021 Jan 1, 2022 $77.41M Feb 16, 2022
FY2021 Oct 2, 2021 $67.61M Feb 16, 2022
FY2021 Jul 3, 2021 $65.14M Feb 16, 2022
FY2021 Apr 3, 2021 $65.66M Feb 16, 2022
FY2020 Jan 2, 2021 $64.90M Feb 23, 2021
FY2021 Sep 26, 2020 $59.70M Feb 16, 2022

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2025 Jan 3, 2026 $126.40M Feb 27, 2026
FY2025 Dec 28, 2024 $182.20M Feb 27, 2026
FY2025 Dec 30, 2023 $130.50M Feb 27, 2026
FY2024 Dec 31, 2022 $191.40M Feb 25, 2025
FY2023 Jan 1, 2022 $137.20M Feb 28, 2024
FY2022 Jan 2, 2021 $118.70M Mar 1, 2023
FY2021 Dec 28, 2019 $93.30M Feb 16, 2022
FY2020 Dec 29, 2018 $81.01M Feb 23, 2021
FY2019 Dec 30, 2017 $65.23M Feb 19, 2020
FY2018 Dec 31, 2016 $57.69M Feb 26, 2019

SG&A Expense

Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.

Fiscal Year Period End Value Filed
FY2025 Jan 3, 2026 $506.00M Feb 27, 2026
FY2025 Dec 28, 2024 $548.60M Feb 27, 2026
FY2025 Dec 30, 2023 $451.30M Feb 27, 2026
FY2024 Dec 31, 2022 $657.40M Feb 25, 2025
FY2023 Jan 1, 2022 $395.40M Feb 28, 2024
FY2022 Jan 2, 2021 $369.00M Mar 1, 2023
FY2021 Dec 28, 2019 $314.66M Feb 16, 2022
FY2020 Dec 29, 2018 $285.42M Feb 23, 2021
FY2019 Dec 30, 2017 $273.01M Feb 19, 2020
FY2018 Dec 31, 2016 $254.71M Feb 26, 2019

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2025 Jan 3, 2026 $217.80M Feb 27, 2026
FY2025 Dec 28, 2024 $196.40M Feb 27, 2026
FY2025 Dec 30, 2023 $94.10M Feb 27, 2026
FY2024 Dec 31, 2022 $29.40M Feb 25, 2025
FY2023 Jan 1, 2022 $264.60M Feb 28, 2024
FY2022 Jan 2, 2021 $211.10M Mar 1, 2023
FY2021 Dec 28, 2019 $221.64M Feb 16, 2022
FY2020 Dec 29, 2018 $239.53M Feb 23, 2021
FY2019 Dec 30, 2017 $56.06M Feb 19, 2020
FY2018 Dec 31, 2016 $419.13M Feb 26, 2019

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2025 Jan 3, 2026 $19.40M Feb 27, 2026
FY2025 Dec 28, 2024 $21.10M Feb 27, 2026
FY2025 Dec 30, 2023 $38.40M Feb 27, 2026
FY2024 Dec 31, 2022 $52.80M Feb 25, 2025
FY2023 Jan 1, 2022 $25.50M Feb 28, 2024
FY2022 Jan 2, 2021 $72.50M Mar 1, 2023
FY2021 Dec 28, 2019 $68.38M Feb 16, 2022
FY2020 Dec 29, 2018 $17.13M Feb 23, 2021
FY2019 Dec 30, 2017 $43.68M Feb 19, 2020
FY2018 Dec 31, 2016 $19.71M Feb 26, 2019

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 Jan 3, 2026 $1.70B Feb 27, 2026
FY2025 Dec 28, 2024 $2.63B Feb 27, 2026
FY2024 Dec 30, 2023 $3.04B Feb 25, 2025
FY2023 Dec 31, 2022 $3.21B Feb 28, 2024
FY2022 Jan 1, 2022 $1.89B Mar 1, 2023
FY2021 Jan 2, 2021 $1.71B Feb 16, 2022
FY2020 Dec 28, 2019 $1.40B Feb 23, 2021
FY2019 Dec 29, 2018 $1.15B Feb 19, 2020
FY2018 Dec 30, 2017 $905.44M Feb 26, 2019
FY2017 Dec 31, 2016 $820.53M Feb 28, 2018

Total Liabilities

All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.

Fiscal Year Period End Value Filed
FY2025 Jan 3, 2026 $977.70M Feb 27, 2026
FY2025 Dec 28, 2024 $1.57B Feb 27, 2026
FY2024 Dec 30, 2023 $1.68B Feb 25, 2025
FY2023 Dec 31, 2022 $1.87B Feb 28, 2024
FY2022 Jan 1, 2022 $336.80M Mar 1, 2023
FY2021 Jan 2, 2021 $304.91M Feb 16, 2022
FY2020 Dec 28, 2019 $228.25M Feb 23, 2021
FY2019 Dec 29, 2018 $185.75M Feb 19, 2020
FY2018 Dec 30, 2017 $181.41M Feb 26, 2019
FY2017 Dec 31, 2016 $260.29M Feb 28, 2018

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 Jan 3, 2026 $721.20M Feb 27, 2026
FY2025 Dec 28, 2024 $1.05B Feb 27, 2026
FY2025 Dec 30, 2023 $1.36B Feb 27, 2026
FY2025 Dec 31, 2022 $1.34B Feb 27, 2026
FY2024 Jan 1, 2022 $1.55B Feb 25, 2025
FY2023 Jan 2, 2021 $1.41B Feb 28, 2024
FY2020 Dec 28, 2019 $1.17B Feb 23, 2021
FY2019 Dec 29, 2018 $969.07M Feb 19, 2020
FY2018 Dec 30, 2017 $724.03M Feb 26, 2019
FY2017 Dec 31, 2016 $560.24M Feb 28, 2018

Goodwill

An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.

Fiscal Year Period End Value Filed
FY2025 Jan 3, 2026 $101.00M Feb 27, 2026
FY2025 Dec 28, 2024 $96.70M Feb 27, 2026
FY2025 Dec 30, 2023 $98.60M Feb 27, 2026
FY2024 Dec 31, 2022 $445.40M Feb 25, 2025
FY2023 Jan 1, 2022 $100.30M Feb 28, 2024
FY2022 Jan 2, 2021 $103.20M Mar 1, 2023
FY2021 Dec 28, 2019 $22.35M Feb 16, 2022
FY2020 Dec 29, 2018 $23.30M Feb 23, 2021
FY2019 Dec 30, 2017 $20.62M Feb 19, 2020
FY2018 Dec 31, 2016 $19.78M Feb 26, 2019

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 Jan 3, 2026 $1.34B Feb 27, 2026
FY2025 Dec 28, 2024 $1.49B Feb 27, 2026
FY2024 Dec 30, 2023 $1.80B Feb 25, 2025
FY2023 Dec 31, 2022 $1.71B Feb 28, 2024
FY2022 Jan 1, 2022 $1.57B Mar 1, 2023
FY2021 Jan 2, 2021 $1.34B Feb 16, 2022
FY2020 Dec 28, 2019 $1.10B Feb 23, 2021
FY2019 Dec 29, 2018 $931.07M Feb 19, 2020
FY2018 Dec 30, 2017 $737.96M Feb 26, 2019
FY2017 Dec 31, 2016 $589.23M Feb 28, 2018

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2025 Jan 3, 2026 $152.30M Feb 27, 2026
FY2025 Dec 28, 2024 $123.60M Feb 27, 2026
FY2024 Dec 30, 2023 $163.00M Feb 25, 2025
FY2024 Dec 31, 2022 $202.90M Feb 25, 2025
FY2023 Jan 1, 2022 $745.30M Feb 28, 2024
FY2022 Jan 2, 2021 $641.40M Mar 1, 2023
FY2021 Dec 28, 2019 $567.69M Feb 16, 2022
FY2020 Dec 29, 2018 $552.49M Feb 23, 2021
FY2019 Dec 30, 2017 $315.30M Feb 19, 2020
FY2018 Dec 31, 2016 $305.97M Feb 26, 2019

Long-Term Debt

Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.

Fiscal Year Period End Value Filed
FY2025 Jan 3, 2026 $524.30M Feb 27, 2026
FY2024 Dec 28, 2024 $765.20M Feb 25, 2025
FY2023 Dec 30, 2023 $906.00M Feb 28, 2024
FY2022 Dec 31, 2022 $956.70M Mar 1, 2023

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 Jan 3, 2026 (2) Feb 27, 2026
FY2025 Dec 28, 2024 (5) Feb 27, 2026
FY2025 Dec 30, 2023 1 Feb 27, 2026
FY2024 Dec 31, 2022 2 Feb 25, 2025
FY2021 Jan 1, 2022 1 Feb 16, 2022
FY2021 Oct 2, 2021 1 Feb 16, 2022
FY2021 Jul 3, 2021 0 Feb 16, 2022
FY2021 Apr 3, 2021 0 Feb 16, 2022
FY2020 Jan 2, 2021 1 Feb 23, 2021
FY2021 Sep 26, 2020 0 Feb 16, 2022

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 Jan 3, 2026 (2) Feb 27, 2026
FY2025 Dec 28, 2024 (5) Feb 27, 2026
FY2025 Dec 30, 2023 1 Feb 27, 2026
FY2024 Dec 31, 2022 2 Feb 25, 2025
FY2021 Jan 1, 2022 1 Feb 16, 2022
FY2021 Oct 2, 2021 1 Feb 16, 2022
FY2021 Jul 3, 2021 0 Feb 16, 2022
FY2021 Apr 3, 2021 0 Feb 16, 2022
FY2020 Jan 2, 2021 1 Feb 23, 2021
FY2021 Sep 26, 2020 0 Feb 16, 2022

Shares Outstanding

Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.

Fiscal Year Period End Value Filed
FY2025 Jan 3, 2026 52.10M Feb 27, 2026
FY2025 Dec 28, 2024 53.60M Feb 27, 2026
FY2024 Dec 30, 2023 52.80M Feb 25, 2025
FY2023 Dec 31, 2022 52.50M Feb 28, 2024
FY2022 Jan 1, 2022 55.30M Mar 1, 2023
FY2021 Jan 2, 2021 55.25M Feb 16, 2022
FY2020 Dec 28, 2019 53.70M Feb 23, 2021
FY2019 Dec 29, 2018 53.09M Feb 19, 2020
FY2018 Dec 30, 2017 51.64M Feb 26, 2019
FY2017 Dec 31, 2016 51.64M Feb 28, 2018